HSD completes UK Solaraze swoop

Resolute Communications has lost its three-year grip on the UK PR account for Shire Pharmaceuticals’ Solaraze to HSD Communications.

The decision comes just weeks after HSD bagged a UK med ed brief for Solaraze (PRWeek, 13 January) – a treatment for actinic
keratosis, a precursor to skin cancer.

Resolute was involved in a head-to-head pitch against HSD for the PR contract. Its joint CEO Paul Blackburn said: 'We believe we have set a benchmark for awareness of actinic keratosis and wish HSD success.'

NICE released guidance on skin cancer treatment just last month.
The rolling of the entire UK brief into HSD completes a multi-stage brand review that kicked off in the middle of last year.

Resolute continues to handle international work for Shire on the brand.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in